Welcome to our dedicated page for Latigo Biotherapeutics SEC filings (Ticker: LTGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Latigo Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Latigo Biotherapeutics's regulatory disclosures and financial reporting.
Latigo Biotherapeutics, Inc. (symbol LTGO) is conducting an initial public offering of 19,200,000 shares of common stock at $18.00 per share, for a gross offering size of $345.6 million, plus a 30‑day underwriters’ option to buy up to 2,880,000 additional shares. Net proceeds are estimated at $315.7 million, to fund Phase 3 development and NDA submission for acute pain candidate LTG‑001, Phase 2–3 development of chronic pain candidate LTG‑321, advancement of early‑stage Nav1.8 inhibitor LTG‑418, and general corporate purposes.
Latigo is a clinical‑stage company developing non‑opioid Nav1.8 inhibitors for acute and chronic musculoskeletal pain, with LTG‑001 showing positive abdominoplasty trial results and LTG‑321 in a Phase 2 osteoarthritis trial. The company reported a $109.2 million net loss in 2025 and had an accumulated deficit of $266.1 million, with auditors including a going‑concern explanatory paragraph.
Latigo Biotherapeutics, Inc. (LTGO) reports that several affiliated 5AM entities hold preferred stock that is convertible into Common Stock on a one-for-one basis. These are reported as indirect holdings by 5AM Ventures VI, L.P. and 5AM Opportunities II, L.P.
The Series A, Series A-2 and Series B Preferred Stock are each convertible at the option of the holder and will automatically convert into Common Stock upon closing of Latigo’s initial public offering without payment of consideration, and have no expiration date. Control and economic interest are allocated among 5AM Ventures VI, L.P., its general partner 5AM Partners VI, LLC, 5AM Opportunities II, L.P., its general partner 5AM Opportunities II (GP), LLC, and managing members Dr. Kush Parmar and Andrew J. Schwab, each of whom disclaims beneficial ownership except to the extent of their pecuniary interest.
Latigo Biotherapeutics, Inc. (LTGO) had an initial Form 3 beneficial ownership report filed by Kevin Raidy, who is identified as a director of the company. The filing lists no reportable transactions or holdings, indicating that no equity positions are being reported at this time.
Latigo Biotherapeutics, Inc. (LTGO) reports initial holdings for director Timothy P. Walbert on a Form 3. He holds director stock options to purchase common stock with exercise prices of $2.19 and $5.53, expiring between 2034-10-29 and 2035-04-07. These options cover up to 259,770, 38,914, and 31,135 underlying shares, which vest over multi-year schedules and are early exercisable, subject to the issuer’s right of repurchase.
Latigo Biotherapeutics, Inc. (LTGO) reported initial insider holdings for Chief Medical Officer Neil Singla. He holds four employee stock options for common stock: one covering 613,468 shares at an exercise price of $2.19 expiring in 2034, and three covering 293,517, 49,480, and 98,960 shares at $5.53 expiring in 2035. Footnotes describe time-based vesting, with one-fourth vesting after one year and the remainder vesting monthly over four years.
Latigo Biotherapeutics, Inc. (LTGO) received an initial ownership report from Beth C. Seidenberg, who is a director and more than 10% owner. The filing lists only indirect holdings in preferred stock series and a convertible note, held through Westlake BioPartners funds and an opportunity fund, each convertible into shares of common stock, generally upon the closing of Latigo’s initial public offering. Seidenberg, as sole managing director of the relevant general partners, has voting and dispositive power over these fund-held securities but disclaims Section 16 beneficial ownership except to the extent of her pecuniary interest.